Clinical trial
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
NCT04030559
Study timeline
Study start (actual)2020-02-25Date precision: day
Registry last updated2026-05-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
ATM Gene Mutationunresolved
BRCA1 Gene Mutationunresolved
BRCA2 Gene Mutationunresolved
BRIP1 Gene Mutationunresolved
CDK12 Gene Mutationunresolved
CHEK1 Gene Mutationunresolved
CHEK2 Gene Mutationunresolved
DNA Damage Response Gene Mutationunresolved
DNA Repair Gene Mutationunresolved
FANCA Gene Mutationunresolved
FANCD2 Gene Mutationunresolved
FANCL Gene Mutationunresolved
GEN1 Gene Mutationunresolved
NBN Gene Mutationunresolved
Prostate Carcinomaunresolved
RAD51 Gene Mutationunresolved
RAD51C Gene Mutationunresolved
Interventions
NiraparibDRUG · verified · RxNorm: niraparib
Niraparib Tosylate MonohydrateDRUG · verified · RxNorm: niraparib tosylate monohydrate
Radical ProstatectomyPROCEDURE
Sponsors & collaborators
University of California, Davislead sponsor
National Cancer Institute (NCI)collaborator
Janssen, LPcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04030559 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.